EarlySense Names John Dragovits as New SVP of Strategic Partnerships

Matt Johnson, EarlySense CEO notes, “Partner collaboration has played an important role in EarlySense’s growth and has been instrumental in helping us reach our goal of establishing contact-free continuous monitoring as a standard of care.” Johnson added, “We look forward to tapping into John’s expertise to strengthen current strategic partnerships and help bring in new relationships that will enable us to continue to elevate patient safety and care.”

John Dragovits has more than 30 years of experience as a healthcare and healthcare IT executive leader. He previously served in VP roles with electronic health records companies Cerner Corporation (Nasdaq: CERN) as well as Senior Vice President and General Manager of Revenue Cycle at Allscripts (Nasdaq: MDX). He was also held health system senior executive roles, having served as Chief Financial Officer and Chief Operating Officer of Dallas’ Children’s Health and Executive VP and CFO of Parkland Health & Hospital System.  Mr. Dragovits is a former U.S. Navy Officer as well as a CPA and holds graduate and undergraduate degrees from Rice University.

“EarlySense is a recognized innovator within the patient monitoring markets, and has played an important role in advancing patient safety and outcomes in healthcare facilities worldwide,” said Dragovits. “I am honored to join the EarlySense team and to explore new avenues to bring contact-free continuous monitoring to even more patients, families and health teams.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”